Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group has scheduled a board meeting for 24 March 2026 to review and approve the audited annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consider recommending a final dividend, if applicable, and may address other business items, signaling upcoming disclosure on profitability and potential shareholder returns.
The announcement confirms the current composition of Livzon’s board, including executive, non-executive, employee representative and independent non-executive directors. This structure underlines the company’s established governance framework as it approaches its annual results cycle, a key event for investors monitoring performance and capital allocation policy.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company engaged in the development, manufacture and sale of medicines and related healthcare products. Listed in Hong Kong, the company operates through a group structure, with subsidiaries contributing to its results and a diversified board overseeing strategic and financial decisions.
YTD Price Performance: 1.82%
Average Trading Volume: 686,458
Technical Sentiment Signal: Buy
Current Market Cap: HK$32.49B
For detailed information about 1513 stock, go to TipRanks’ Stock Analysis page.